{"id":1835,"date":"2019-09-26T01:04:29","date_gmt":"2019-09-25T23:04:29","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1835"},"modified":"2024-10-14T13:19:10","modified_gmt":"2024-10-14T11:19:10","slug":"hereditary-cancer","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/hereditary-cancer\/","title":{"rendered":"Hereditary cancer"},"content":{"rendered":"\n

\n\t\tHereditary cancer\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\tWe are a multidisciplinary research group working on Hereditary Cancer at the Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL) and the Institute for Health Science Research Germans Trias i Pujol (IGTP). Our work, whether clinical- or research-oriented, is focused on the improvement of healthcare of patients with a personal or a family history of cancer.
\nAs may be observed in the Research Lines section, the overarching goal of our research activity is to gain insight into the molecular bases of hereditary cancer -with a particular interest in gastrointestinal cancer, Hereditary Breast and Ovarian Cancer and Rare Tumor predisposing syndromes – in order to personalize risk assessment for patients and relatives, as well as to individualize management regarding follow-up, treatment, and prophylactic and preventive measures. The group participates in international and national initiatives aimed to improve variant classification in hereditary cancer genes, define clinical guidelines for hereditary cancer patients, and implement genomic-based personalized medicine in the National Health System\n

1243<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"114-cancerhereditari-capella-2def_2\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t
    \n
  1. Improvement of genetic testing strategies<\/li>\n
  2. Development of strategies to refine variant classification in hereditary cancer genes<\/li>\n
  3. Personalization of cancer risks, prevention and treatment<\/li>\n
  4. Identification of new genes and mechanisms involved in the predisposition to colorectal cancer and polyposis<\/li>\n
  5. Identification of new genes and mechanisms of rare tumor predisposition syndromes.<\/li>\n
  6. Establishment, optimization, and implementation of state-of-the-art models<\/li>\n
  7. Identification and assessment of novel quantitative (epi)mutational biomarkers in tumors, target tissues and surrogate minimally invasive samples<\/li>\n
  8. Participation and leadership in National and Regional initiatives of genomic-based precision medicine in cancer<\/li>\n
  9. Refinement of therapeutic approaches for Neurofibromatosis type 1<\/li>\n
  10. Development of research resources for patients, health care providers and researchers interested in rare ovarian tumors.<\/li>\n
  11. Refinement of molecular mechanisms of miRNA biogenesis defective tumors.<\/li>\n<\/ol>\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t